Just wrapped up a huge day of amazing talk and engaging discussions! Special thanks to all our sponsors, international and interstate guests and everyone who braved the weather to make it today! #drugdev#oncology#collaboration
Our latest podcast is now out! Redefining frustration to success, career insights with Neil Fleshner. We hear about his medical career, launching a successful radio-ligand startup company, and advice for others interested in the space! #biofinance#urology https://t.co/MNoWYNMHuS
Looking forward to meeting everyone tomorrow at our annual Drug Development Meeting! Last chance to register and join us for a day exploring the frontiers in clinical development! https://t.co/PHy7id9tqq
Only 1 week left until our annual Drug Development Meeting! We can't wait to see everyone there and welcome our international guest speakers! If you haven't registered yet, don't forget to get a ticket at: https://t.co/PHy7id9tqq
Only a few weeks left until our annual Drug Development Meeting! We can't wait to see everyone there and welcome our international guest speakers! If you haven't registered yet, don't forget to get a ticket at: https://t.co/PHy7id9tqq
Don't forget to register for our Drug Development Meeting 2026! We have a great panel for the day, from global investigators to biotech. Registrations free for academic affiliations and open at the link: https://t.co/PHy7id9tqq
Don't forget to register for our Drug Development Meeting 2026! We have a great panel for the day, from global investigators to biotech. Registrations free for academic affiliations and open at the link: https://t.co/PHy7id9tqq
Registrations are now open for our annual Drug Development Meeting 2026! - Join us for an exciting day meeting with experts in early phase oncology from around the globe!
Registration link below:
https://t.co/PHy7id9tqq
Join us as we bring the year to a close by chatting with about how ctDNA testing can inform better treatment decisions in the clinic. We hear about the power of ctDNA + tumour informed testing and the latest data supporting it's use in GI + other cancers. https://t.co/PIiQrlCA6s
Congratulations Associate Professor @AbhijitPal, Medical Oncologist at @SouthWesternSydneyLocalHealthDistrict – winner of the 2025 Improving Equitable Outcomes through Cancer Research Award. #CancerNSWAwards
Congratulations Associate Professor Inês Esteves Domingues Pires da Silva – 2025 Outstanding Mid Career Researcher of the Year. A/Prof Pires da Silva is a distinguished Medical Oncologist and Associate Professor at the @MelanomaAus and @Sydney_Uni. #CancerNSWAwards
We're back after a fascinating talk with Dr Laura Chang at @arteraAI about predictive use of AI in digitalised pathology. Tune in to hear more about how tech is improving prognostic and predictive cancer care outcomes! #AI#cancercare#tech https://t.co/P0e6eMUZdw
Delighted to share 2 posters @myESMO#ESMO25 - poster award for GRWD5769 ERAP1 inhibitor in adv solid tumors, and @NECTANSW PANNA-COTA study matching 🩸 🧬 with early phase trial enrolment
🙏 to participating patients carers and collaborating sites
While potentially practice changing few of these are immediately actionable in the real world 🌏 due to delays in funding, approval and access.
🗺️ regulatory harmonisation needed to bring 🔬💊 from the podium into everyday practice for our patients who waiting 🩺👩⚕️💕 #ESMO25
Looking forward to #ESMO25, where clinicians will share results from research collaborations with Guardant Health AMEA, and new real-world data across solid tumor types.
A heartfelt thank you to the researchers and collaborators @JiaJennyLiu, @docrohatgi Nir Peled, Amit Rauthan, Shota Fukuoka, @kobashin0117, @Hiroki_Osumi, and Seiichiro Mitani.
We remain committed to collaborating with clinicians to advance real-world evidence in precision oncology.
Great to see the work of NECTA on early phase clinical trials - presented by Dr Rasha Cosman, @GarvanInstitute. The Cancer Institute NSW is proud to support this incredible work across the state. #NSWCancerSummit2025
The NECTA team will be attending ASCO 2025 in Chicago and welcome meetings to talk about phase 1 trials in Australia. Feel free to reach out! #NECTANSW#drugdevelopment#phase1